SELLAS Life Sciences Group, Inc.(SLS)Earnings, Financials & Key RatiosSELLAS Life Sciences Group, Inc. (SLS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on equity issuance to offset persistent net losses, which totaled $8.4 million in 2026Q1 alone, presents significant dilution risk for long-term shareholders.
SELLAS Life Sciences Group, Inc. (SLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
SELLAS Life Sciences Group, Inc. (SLS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.05vs $0.06+16.7% | — |
| Q2 2026 | Mar 19, 2026 | $0.05vs $0.06+21.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.06vs $0.06+5.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.07vs $0.08+16.0% | — |
Recent stock market news and headlines for SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.
[url="]Amentum[/url] (NYSE: AMTM), a global leader in advanced engineering and technology solutions, has been awarded NASA's Consolidated Spaceflight Mission O
SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.
Key metrics vs top competitors for SELLAS Life Sciences Group, Inc. (SLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.94 | $1.99B | -55.76 | — | — | -66.88% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $9.16 | $2.12B | 15.27 | 19.63% | 32.43% | 38.97% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — | |
| $37.95 | $2.53B | -9.73 | -78.63% | -34596.22% | -50.72% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — |
SELLAS Life Sciences Group, Inc. (SLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SELLAS Life Sciences Group, Inc. (SLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
Mar 19, 2026·SEC
Mar 11, 2026·SEC
Get notified when SLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SELLAS Life Sciences Group, Inc. (SLS) stock FAQ — growth, dividends, profitability & financials explained
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $29.5M for fiscal year 2025.
SELLAS Life Sciences Group, Inc. (SLS) has a return on equity (ROE) of -66.9%. Negative ROE indicates the company is unprofitable.
SELLAS Life Sciences Group, Inc. (SLS) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.
